TIDMCTEA
Catenae Innovation PLC
02 August 2021
2 August 2021
Catenae Innovation PLC
("Catenae" or the "Company")
Collaboration agreement with ProMake Limited
Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of
digital media and technology, announces that it has signed a
collaboration agreement with ProMake Limited ("ProMake"), a global
specialist in material science and medical innovations. Under the
terms of the agreement, Catenae will be the exclusive provider of
data management services to ProMake to fulfil its position on the
Public Health England ("PHE") National Microbiology Framework.
ProMake has unique intellectual property and technology that
utilises graphene and other nano-materials within an injection
moulded 'PreVent' tube, which a patient blows into in order to
provide medical samples. The test may be used to diagnose many
different diseases using a much less invasive method and at a
potentially lower cost to conventional methods. Initially, the
PreVent tube will be processed in a lab but ProMake's aim is to
build an inexpensive 'Bio-Pod' device that will analyse the sample
locally and pass data to a cloud based platform for diagnosis via
an individual's mobile app.
The National Microbiology Framework, announced by PHE in
November 2020, supports the newly formed UK Health Security Agency
(UKHSA) and the Government's effort to provide a broad range of
medical testing and diagnostic services for people in the UK. More
information on the Framework can be found via this link:
https://www.government-online.net/national-microbiology-framework-public-health-england/
Catenae forms part of a ProMake led consortium which has been
awarded positions in Lot 2 (Research and Development Goods and
Services) and Lot 4 (Clinical Laboratoty Diagnostic Testing
Services) of the PHE Framework Agreement. Other consortium members
include Haydale Graphene Industries plc (AIM:HAYD), the advanced
materials group that will be the manufacturing and exclusive nano
materials partner to the consortium. Haydale recently made the
following announcement in relation to the ProMake led consortium,
which can be found via this link:
https://www.haydale-ir.com/content/news/archive/2021/120721
Catenae's role within the consortium will be to securely capture
and process patient and test data, control access to that data in a
compliant manner and provide reporting services through dashboards,
mobile apps, web and blockchain technology. ProMake's intention is
to automate all aspects of the supply chain from the manufacture,
distribution and use of the Pre-Vent tubes through to their
ultimate disposal. Catenae will manage the data throughout that
supply chain and where appropriate make the data available to
individuals and organisations.
Under this collaboration agreement, Catenae will also provide
consulting services to support ProMake in its engagement with the
organisations able to access the Framework Agreement, which
includes:
-- Public Health England;
-- Department of Health and Social Care;
-- Public Health Wales;
-- Public Health Scotland;
-- Department for Health for Northern Ireland;
-- Health and Social Care Northern Ireland;
-- NHS Authorities, NHS Trusts, NHS Foundation Trusts, Special
Health Authorities, NHS Scotland Health Boards, NHS Wales Health
Boards, NHS Northern Ireland Health Boards, Special NHS Boards and
any other NHS entity;
-- Local Authorities;
-- Any other bodies governed by public law (as defined in
regulation 2 of the Public Contracts Regulations 2015 (SI 2015/102)
(as amended); and
-- Academic or charitable institutions (including any such institutions that are not Contracting Authorities).
The Catenae Board considers that it is premature to provide any
guidance as to the timing or value to Catenae of this
collaboration, but anticipates being able to give a more detailed
update in the coming months.
Guy Meyer, Chief Executive Officer of Catenae, said: "We are
delighted to announce this collaboration agreement with ProMake to
support its work within the Public Health England National
Microbiology Framework. Our provision of data management services
and support in Lots 2 and 4 of the framework demonstrates the
digital transformational application of Catenae's innovative
technologies, as well as the Company's continued commitment to
delivering people centric technology solutions.
"Our data management services can be successfully applied to a
number of sectors and industries, with Covid-19 testing and related
services a continued area of work for Catenae."
Jason Laing, Co-Founder and CEO of ProMake, said: "On behalf of
ProMake, I would like to thank Catenae for the support it has given
us through this tender process. We are excited to work with Catenae
and employ its data management services to fulfil our position on
the National Microbiology Framework."
- Ends -
For further information please contact:
+44 (0)191 580
Catenae Innovation PLC 8545
Guy Meyer, Chief Executive Officer
+44 (0)20 3463
Brandon Hill Capital Limited, Broker 5000
Andy Gutmann
+44 (0)20 3004
Yellow Jersey PR (PR & IR) 9512
Sarah Hollins / Annabel Atkins / Matthew McHale
Notes to Editors:
About Catenae Innovation PLC
Catenae Innovation is an AIM quoted provider of digital media
and technology services. Catenae use the power of blockchain to
deliver solutions where its people-centric technology enables trust
and certainty allowing organisations to gain better control over
their operations, manage staff and safely welcome customers.
www.catenaeinnovation.com
About ProMake Limited
ProMake specialises in the design, development and manufacturing
of medical innovations and devices. It engages in fabricating
medical diagnostic and therapeutic apparatus, marketing &
distribution.
www.promake.com
About Haydale
Haydale is a global technologies and materials group that
facilitates the integration of graphene and other nanomaterials
into the next generation of commercial technologies and industrial
materials.
https://haydale.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKKBNPBKDAON
(END) Dow Jones Newswires
August 02, 2021 02:00 ET (06:00 GMT)
Catenae Innovation (LSE:CTEA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Catenae Innovation (LSE:CTEA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
